Video

Dr. McDermott on Targeting PD-1/PD-L1 in Kidney Cancer

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of agents that target PD-1 or PD-L1 as treatments for patients with kidney cancer.

McDermott says data so far for treatments that target PD-1 or PD-L1 in patients with kidney cancer has been remarkable, specifically since many tumors express PD-L1 on the cell surface, as a way of avoiding being attacked by the immune system.

This ability of the tumor to supress the immune system can now be blocked with the administration of monoclonal antibodies, states McDermott. These agents bind to the ligand (PD-L1) or its receptor on the T cell (PD-1) resulting in a recovery of T cell function that causes antitumor activity.

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD